Streetbeat News

Products Services

BTCUSD

Bernstein's report indicates the slowdown in Bitcoin ETF inflows is a temporary pause, not a negative trend. The report suggests a future integration with private bank platforms and wealth advisors, maintaining a projection of a Bitcoin cycle high of $150,000 by 2025. Despite recent outflows, the bitcoin mining cycle remains healthy, and the market is in a consolidation phase, hinting at potential future upswings.

Portfolio Pulse from Benzinga Neuro

April 29, 2024 | 11:27 am

MNKD

MannKind Corporation's stock price increased following the FDA's approval of its Investigational New Drug (IND) application for MNKD-10, signaling a positive development in the company's drug pipeline.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:17 am

ARQQ

INTC

Arqit Quantum Inc. has partnered with Intel to launch the world's first quantum-safe 1.89 Tb IPsec products, utilizing Arqit's Symmetric Key Agreement Platform on Intel Xeon Scalable processors. This collaboration aims to provide high-performance encryption solutions that guard against quantum attacks, with financial terms not disclosed.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:08 am

TECH

TMO

Bio-Techne will partner with Thermo Fisher Scientific for the distribution of its products across Europe starting May 1, 2024. This agreement enables Thermo Fisher to distribute Bio-Techne's portfolio, including antibodies, proteins, and reagents, through its Fisher Scientific Channel in Europe.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:07 am

PRME

Prime Medicine has received FDA clearance for its Investigational New Drug application for PM359, aimed at treating Chronic Granulomatous Disease. The company anticipates reporting initial clinical data from the study in 2025.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:05 am

AQST

Aquestive Therapeutics has received FDA approval and market access for its Libervant Buccal Film for pediatric patients aged 2 to 5. This approval marks a significant milestone for the company, expanding its product's reach to a younger demographic and potentially boosting its market presence in treatments for this age group.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:04 am

LH

PFE

The FDA has approved Labcorp's nAbCyte Anti-AAVRh74var HB-FE, a companion diagnostic for determining patient eligibility for Beqvez, Pfizer's FDA-approved gene therapy for Hemophilia B. This marks a significant advancement in personalized medicine for Hemophilia B treatment.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:04 am

PUMP

XOM

ProPetro Holding Corp. (PUMP) has signed a three-year agreement to provide electric hydraulic fracturing services to ExxonMobil (XOM) in the Permian Basin. This deal marks a significant strategic step for ProPetro, emphasizing its commitment to sustainability and operational excellence in its long-term partnership with ExxonMobil.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:04 am

REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced positive long-term results and subgroup analyses for EYLEA HD (aflibercept) Injection 8 mg at the ARVO annual meeting. The data is part of 14 abstracts on EYLEA HD and EYLEA (aflibercept) Injection 2 mg being presented.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:02 am

PRME

Prime Medicine, Inc. (NASDAQ:PRME) announced FDA clearance for its IND application for PM359, aimed at treating chronic granulomatous disease (CGD). This approval allows the initiation of a global Phase 1/2 clinical trial in the United States.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 11:01 am